Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been given a consensus rating of “Hold” by the eleven research firms that are covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $7.42.

A number of research firms have commented on CLDX. Zacks Investment Research cut shares of Celldex Therapeutics from a “buy” rating to a “sell” rating in a research note on Monday, July 17th. BidaskClub cut shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday. Cowen and Company reissued a “buy” rating on shares of Celldex Therapeutics in a research note on Tuesday, June 6th. Aegis reissued a “buy” rating on shares of Celldex Therapeutics in a research note on Thursday, June 29th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $3.50 price target (down previously from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, May 11th.

Shares of Celldex Therapeutics (CLDX) traded up 0.42% during mid-day trading on Tuesday, reaching $2.40. 1,079,145 shares of the company’s stock were exchanged. The firm’s market cap is $300.25 million. The company has a 50 day moving average price of $2.45 and a 200 day moving average price of $3.12. Celldex Therapeutics has a 52-week low of $2.20 and a 52-week high of $5.02.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.28) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.28). Celldex Therapeutics had a negative net margin of 1,825.82% and a negative return on equity of 53.10%. The business had revenue of $1.53 million during the quarter, compared to analysts’ expectations of $0.57 million. Analysts forecast that Celldex Therapeutics will post ($1.11) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Hold” by Analysts” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/07/25/celldex-therapeutics-inc-nasdaqcldx-given-consensus-recommendation-of-hold-by-analysts.html.

Several large investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Celldex Therapeutics by 16.4% in the first quarter. Vanguard Group Inc. now owns 9,066,763 shares of the biopharmaceutical company’s stock worth $32,731,000 after buying an additional 1,278,206 shares during the period. Meditor Group Ltd boosted its stake in shares of Celldex Therapeutics by 39.9% in the second quarter. Meditor Group Ltd now owns 5,800,000 shares of the biopharmaceutical company’s stock worth $14,326,000 after buying an additional 1,654,100 shares during the period. State Street Corp boosted its stake in shares of Celldex Therapeutics by 4.7% in the first quarter. State Street Corp now owns 4,525,051 shares of the biopharmaceutical company’s stock worth $16,341,000 after buying an additional 202,375 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Celldex Therapeutics by 42.4% in the first quarter. Renaissance Technologies LLC now owns 1,707,927 shares of the biopharmaceutical company’s stock worth $6,166,000 after buying an additional 508,217 shares during the period. Finally, TSP Capital Management Group LLC boosted its stake in shares of Celldex Therapeutics by 20.0% in the first quarter. TSP Capital Management Group LLC now owns 1,063,248 shares of the biopharmaceutical company’s stock worth $3,838,000 after buying an additional 176,850 shares during the period. 64.54% of the stock is owned by institutional investors.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.